• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LUMO

    Lumos Pharma Inc.

    Subscribe to $LUMO
    $LUMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

    IPO Year: 2011

    Exchange: NASDAQ

    Website: lumos-pharma.com

    Peers

    $HOOK
    $XBIT

    Recent Analyst Ratings for Lumos Pharma Inc.

    DatePrice TargetRatingAnalyst
    11/4/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    7/21/2021$34.00 → $27.00Buy
    HC Wainwright & Co.
    See more ratings